Identification of a new HLA-A*0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen

International Journal of Cancer

Volumn 87, Issue 3, 2000, Pages 399-404

  Sun, Yuansheng ^a   Song, Mingxia ^a   Stevanović, Stefan ^b   Jankowiak, Carsten ^a   Paschen, Annette ^a   Rammensee, Hans Georg ^b   Schadendorf, Dirk ^a,c  

^a Clin Coop U for Dermato Oncology   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A ANTIGEN; MELANOMA ANTIGEN; T LYMPHOCYTE RECEPTOR; TYROSINASE RELATED PROTEIN 2;

ANIMAL CELL; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; MELANOMA; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; RECEPTOR AFFINITY; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

AMINO ACID MOTIFS; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; COS CELLS; DENDRITIC CELLS; EPITOPES; HLA-A2 ANTIGEN; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; LYMPHOCYTE ACTIVATION; MELANOMA; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0034255894     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20000801)87:3<399::AID-IJC14>3.0.CO;2-9     Document Type: Article

References (27)

1. BÖHM, C.M., HANSKI, M.L., STEFANOVIĆ, S., RAMMENSEE, H.-G., STEIN, H., TAYLOR-PAPADIMITRIOU, J., RIECKEN, E.O., and HANSKI, C., Identification of HLA-A2-restricted epitopes of the tumor-associated antigen MUC2 recognized by human cytotoxic T cells. Int. J. Cancer, 75, 688-693 (1998).
2. BOON, T., COULIE, P.G., and VAN DEN EYNDE, B., Tumor antigens recognized by T cells. Immunol. Today, 18, 267-268 (1997).
3. CASTELLI, C., TARSINI, P., MAZZOCCHI, A., RINI, F., RIVOLTINI, L., RAVAGNANI, F., GALLINO, F., BELLI, F., and PARMIANI, G., Novel HLA-Cw8- restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens. J. Immunol., 162, 1739-1748 (1999).
4. CELIS, E., FIKES, J., WENTWORTH, P., SIDNEY, J., SOUTHWOOD, S., MAEWAL, A., DEL GUERCIO, M.F., SETTE, A., and LIVINGSTON, B., Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. Mol. Immunol., 31, 1423-1430 (1994).
5. DE VRIES, T.J., FOURKOUR, A., WOBBES, T., VERKROOST, G., RUITER, D.J., and VAN MUIJEN, G.N., Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res., 57, 3223-3229 (1997).
6. + tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Europ. J. Immunol., 24, 1966-1973 (1994).
7. HEO, D.S., PARK, J.G., HATA, K., DAY, R., HERBERMAN, R.B., and WHITESIDE, T.L., Evaluation of tetrazolium-based semi-automatic colorimetric assay for measurement of human anti-tumor cytotoxicity. Cancer Res., 50, 3681-3690 (1990).
8. + cytotoxic T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer, 66, 470-476 (1996).
9. JONULEIT, H., KÜHN, U., MÜLLER, G., STEINBRINK, K., PARAGNIK, L., SCHMITT, E., KNOP, J., and ENK, A., Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Europ. J. Immunol., 27, 3135-3142 (1997).
10. MARCHAND, M., and 24 OTHERS, Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer, 80, 219-230 (1999).
11. MARINCOLA, F.M., VENZON, D., WHITE, D., RUBIN, J.T., LOTZE, M.T., SIMONIS, T.B., BALKISSOON, J., ROSENBERG, S.A., and PARKINSON, D.R., HLA association with response and toxicity in melanoma patients treated with interleukin-2-based immunotherapy. Cancer Res., 52, 6561-6566 (1992).
12. NESTLE, F.O., ALIJAGIC, S., GILLIET, M., SUN, Y., GRABBE, S., DUMMER, R., BURG, G., and SCHADENDORF, D., Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature (Med.), 4, 328-332 (1998).
13. ORLOW, S.J., SILVERS, W.K., ZHOU, B.-K. and MINTZ, B., Comparative decreases in tyrosinase, TRP1, TRP2, and Pmel 17/Silver antigenic proteins from melanotic to amelanotic stages of syngeneic mouse cutaneous melanomas and metastases. Cancer Res., 58, 1521-1523 (1998).
14. PARKHURST, M.R., FITZGERALD, E.B., SOUTHWOOD, S., SETTE, A., ROSENBERG, S.A., and KAWAKAMI, Y., Identification of a shared HLA-A*0201-restricted T-cell epitopes from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res., 58, 4895-4901 (1998).
15. RAMMENSEE, H.-G., FRIEDE, T., and STEVANOVIĆ, S., MHC ligands and peptide motifs: first listing. Immunogenetics, 41, 178-228 (1995).
16. REINTGEN, D.S., MCCARTY, K.M., JR., COX, E., and SEIGLER, H.F., Malignant melanoma in black American and white American populations: a comparative review. J. amer. med. Assoc., 248, 1856-1859 (1982).
17. + T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J. Immunol., 161, 6970-6976 (1998).
18. ROSENBERG, S.A., A NEW ERA FOR CANCER IMMUNOTHERAPY BASED ON THE GENES THAT ENCODE CANCER ANTIGENS. Immunity, 10, 281-287 (1999).
19. ROSENBERG, S.A., YANG, J.C., SCHWARTZENTRUBER, D.J., HWU, P., MARINCOLA, F.M., TOPALIAN, S.L., RESTIFO, N.P., DUDLEY, M.E., SCHWARZ, S.L., SPIESS, P.J., WUNDERLICH, J.R., PARKHURST, M.R., KAWAKAMI, Y., SEIPP, C.A., EINHORN, J.H., and WHITE, D.E., Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature (Med.), 4, 321-327 (1998).
20. SUN, Y., JURGOVSKY, K., MÖLLER, P., ALIJAGIC, S., DORBIC, T., GEORGIEVA, J., WITTIG, B., and SCHADENDORF, D., Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther., 5, 481-490 (1998).
21. SUN, Y., PASCHEN, A., and SCHADENDORF, D., Cell-based vaccination against melanoma: background, preliminary results, and perspective. J. mol. Med., 77, 593-608 (1999).
22. TRAVERSARI, C., VAN DER BRUGGEN, P., VAN DEN EYNDE, B., HAINAUT, P., LEMOINE, C., OHTA, N., OLD, L., and BOON, T., Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics, 35, 145-152 (1992).
23. TSAI, V., SOUTHWOOD, S., SINDEY, J., SAKAGUCHI, K., KAWAKAMI, Y., APPELLA, E., SETTE, A., and CELIS, E., Identification of subdominant CTL epitopes of gp100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol., 158, 1796-1802 (1997).
24. VAN DER BRUGGEN, P., BASTIN, J., GAJEWSKI, T., COULIE, P.G., BOEL, P., DE SMET, C., TRAVERSARI, C., TOWNSEND, A., and BOON, T., A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Europ. J. Immunol., 24, 3038-3043 (1994).
25. VAN ELSAS, A., VAN DER BURG, S.H., VAN DER MINNE, C., BORGHI, M., MOURER, J.S., MELIEF, C.J.M., and SCHRIER, P.I., Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen. Europ. J. Immunol., 26, 1683-1689 (1996).
26. WANG, R.F., APPELLA, E., KAWAKAMI, Y., KANG, X., and ROSENBERG, S.A., Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. exp. Med., 184, 2207-2216 (1996).
27. WANG, R.F., JOHNSTON, S.L., SOUTHWOOD, S., SETTE, A., and ROSENBERG, S.A., Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J. Immunol., 160, 890-897 (1998).